On 10/31/24, NovoCure Ltd (NASDAQ: NVCR) stock suffered a major decline of -10.7%, closing at $15.18. This decline was accompanied by normal trading volume. The stock has declined -6.2% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NVCR is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. NovoCure has a very low Appreciation Score of 10 but a neutral Power Rating of 60, producing the Negative Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment